Halogen bonding for the design of inhibitors by targeting the S1 pocket of serine proteases. Issue 49 (6th August 2018)

• Record Type: Journal Article
• Authors: Jiang, Longguang; Zhang, Xu; Zhou, Yang; Chen, Yayu; Luo, Zhipu; Li, Jinyu; Yuan, Cai; Huang, Mingdong
• Is Part Of: RSC advances. Volume 8:Issue 49(2018)
• Page Start: 28189
• Page End: 28197
• Publication Date: 2018-08-06
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/c8ra03145b
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : BrBA binds to the S1 pocket of urokinase with Br facing the base of the pocket by halogen bonds, while iodine of IBA binds to the S1 in the opposite way. Abstract : Halogen bonding (or X bonding) has attracted increasing interest due to its significant role in molecular recognition in biological systems. Trypsin-like serine proteases have many physiological and pathophysiological functions. There is therefore extensive interest in generating specific inhibitors for pharmacological intervention in their enzymatic activity. We study here if it is possible to use halogenated compounds as the P1 group to bind to the S1 specificity pocket of trypsin-like serine proteases to avoid the low bioavailability of the amidine or guanidine P1 group that is typically used in many inhibitors. We used 4-chlorobenzylamine (ClBA), 4-bromobenzylamine (BrBA) and 4-iodobenzylamine (IBA) as probes to test their binding modes to a trypsin-like serine protease, urokinase-type plasminogen activator (uPA), which has been recognized as a marker for breast cancer and an important target for inhibitor development. The results showed that these compounds inhibited uPA with stronger efficacies compared with their non-halogenated analogues. We also determined the high-resolution crystal structures of uPA in complex with BrBA and IBA, respectively. The structures revealed that BrBA bound to the S1 pocket of uPA via halogen bonds, but IBA did not make halogen bonds with uPA, demonstrating that the iodine may not be the best choice as a target moiety for serine proteases. These results advocate halogen bonding, especially bromine bonding, as an efficient strategy for the future design of novel inhibitors against trypsin-like serine proteases to provide strong potency and promote bioavailability.